Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | DPP4 | P27487 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | XBP1 | P17861 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.50 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4528163 | 0.85 | HIF1A (0.71) | SMN1; SMN2DPP4LMNATSHRNPSR1 | |
| SCHEMBL13789635 | 0.84 | DPP4 (0.47) | SMN1; SMN2MAPTDPP4LMNATSHR | |
| SCHEMBL4465299 | 0.79 | L3MBTL1 (0.79) | SMN1; SMN2LMNATSHRNPSR1L3MBTL1 | |
| SCHEMBL13789510 | 0.79 | HIF1A (0.51) | SMN1; SMN2DPP4LMNATSHRHTT | |
| SCHEMBL4507484 | 0.77 | L3MBTL1 (0.61) | SMN1; SMN2LMNATSHRNPSR1L3MBTL1 | |
| SCHEMBL13789634 | 0.75 | L3MBTL1 (0.58) | SMN1; SMN2LMNATSHRNPSR1L3MBTL1 | |
| SCHEMBL2116934 | 0.74 | NPSR1 (0.67) | SMN1; SMN2TP53MAPTDPP4LMNA | |
| SCHEMBL2118435 | 0.72 | MAPT (0.73) | SMN1; SMN2TP53MAPTLMNATSHR | |
| SCHEMBL939933 | 0.72 | ALDH1A1 (0.64) | SMN1; SMN2TP53LMNATSHRHTT | |
| SCHEMBL1592824 | 0.72 | L3MBTL1 (0.60) | SMN1; SMN2MAPTLMNATSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170834-A1 | Fused Pyrimidones and Thiopyrimidones, and Uses Thereof | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170834-A1 | Fused Pyrimidones and Thiopyrimidones, and Uses Thereof | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170834-A1 | Fused Pyrimidones and Thiopyrimidones, and Uses Thereof | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| WO-2007076085-A2 | FUSED PYRIMIDONES AND THIOPYRIMIDONES, AND USES THEREOF | PROLEXYS PHARMACEUTICALS, INC . (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007076085-A2 | FUSED PYRIMIDONES AND THIOPYRIMIDONES, AND USES THEREOF | PROLEXYS PHARMACEUTICALS, INC . (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170834-A1 | Fused Pyrimidones and Thiopyrimidones, and Uses Thereof | TYMP, TYMS, MKI67 | SMN1; SMN2 1145/4885TP53 47/4885MAPT 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.